piperacillin has been researched along with ppi-0903 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biek, D; Ge, Y; Sahm, DF; Talbot, GH | 1 |
| Cheng, B; Guo, P; Jia, P; Xu, Y; Yang, Q; Zhang, H; Zhu, Y | 1 |
2 other study(ies) available for piperacillin and ppi-0903
| Article | Year |
|---|---|
In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
Topics: Anti-Bacterial Agents; Ceftaroline; Cephalosporins; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; United States | 2008 |
In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program.
Topics: Ampicillin; Anti-Bacterial Agents; Azabicyclo Compounds; Ceftaroline; Ceftazidime; Cephalosporins; Colistin; Drug Combinations; Escherichia coli; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Klebsiella pneumoniae; Levofloxacin; Meropenem; Methicillin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Tazobactam; Tigecycline | 2022 |